{"nctId":"NCT05878067","briefTitle":"A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants","startDateStruct":{"date":"2023-06-27","type":"ACTUAL"},"conditions":["Dry Eye Syndrome"],"count":40,"armGroups":[{"label":"ABBV-444","type":"EXPERIMENTAL","interventionNames":["Drug: ABBV-444"]}],"interventions":[{"name":"ABBV-444","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Had used artificial tears for dry eyes within the past year\n* OSDI score of ≥ 18 and ≤ 65 (based upon a 0 to 100 scale) at Screening and Baseline Visits Three consecutive tear breakup time (TBUT) tests ≤ 10 seconds in at least 1 eye at Day -7 (screening)\n* Grade 1 to 4 (modified National Eye Institute \\[NEI\\] Grid, score range = 0 to 5) staining in at least 1 area of the cornea (5 areas examined) or conjunctiva (6 areas examined) that was related to dry eye in at least 1 eye at both at Screening and Baseline Visits\n\nExclusion Criteria:\n\n* Have uncontrolled severe systemic disease that, in the assessment of the investigator, would put safety of the participant at risk through participation, or which would prevent or confound protocol-specified assessments (e.g., hypertension and diabetes, Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, immunodeficiency disease, etc.)\n* Known allergy or sensitivity to the study products or their components\n* Schirmer Test (with anesthesia) ≤ 2 mm in either eye at Screening Visit\n* Participant anticipated contact lens wear during the study, or the participant had worn contact lenses in the last 3 months prior to Screening Visit","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) Score","description":"The OSDI is a 12-question survey for participants to document their dry eye disease symptoms. The OSDI consists of a 5-point scale ranging from 0 (none of the time) to 4 (all of the time), with higher scores representing greater disability. The scores from the 12 questions are totaled and converted to an overall score ranging from 0 (no disability) to 100 (complete disability). A negative number change from baseline represents an improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.8","spread":"15.0"}]}]}]},{"type":"SECONDARY","title":"Patient Eye Drop Experience (PEDE) Survey Scores at Day 30 (Visual Analog Scale)","description":"The PEDE Survey is a 13-item questionnaire that evaluates the short- and long-term subjective experience in comfort and vision as well as tolerability, using a scale ranging from 0 (strongly disagree) to 100 (strongly agree). On Day 30, participants were asked to retrospectively recall their experiences after 5 minutes, 30 minutes, 24 hours, and 5 days of when they administered the eye drops","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.4","spread":"36.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.1","spread":"27.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.3","spread":"25.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":"30.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":"21.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":"25.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":"30.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.6","spread":"20.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":"21.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.4","spread":"20.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":"21.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.8","spread":"23.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":"22.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Symptom Scores (Visual Analog Scale) Within 5 Minutes Post Administration of ABBV-444","description":"The Current Symptom Survey is a 5-item questionnaire where the participants rate their ocular symptoms at the present moment using a scale ranging from 0 (strongly disagree) to 100 (strongly agree). Surveys were completed 5 minutes following the first administration of study eye drops. A negative number change from baseline represents an improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.1","spread":"10.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":[]}}}